| 2026-06-03 | 8-K | 10.1 | 2026 Equity Incentive Plan and related form agreements. |
|---|
| 2026-05-07 | 10-Q | 10.7 | Form of Restricted Share Unit Award Agreement. |
|---|
| 2026-04-13 | 8-K | 10.1 | Amended and Restated 2025 Inducement Equity Plan and related form agreements. |
|---|
| 2026-02-26 | 10-K | 10.41 | Employment Agreement by and between the Company and Darren Cline, effective as of February 25, 2026. |
|---|
| 2026-02-26 | 10-K | 10.40 | Employment Agreement by and between the Company and Christopher Kenny, effective as of February 25, 2026. |
|---|
| 2026-02-26 | 10-K | 10.39 | Employment Agreement by and between the Company and Andrea DiFabio, effective as of February 25, 2026. |
|---|
| 2026-02-26 | 10-K | 10.38 | Employment Agreement by and between the Company and Thomas P. Kelly, effective as of February 25, 2026. |
|---|
| 2026-02-26 | 10-K | 10.37 | Employment Agreement by and between the Company and Ian Mortimer, effective as of February 25, 2026. |
|---|
| 2026-02-26 | 10-K | 10.33 | Post-Employment Consulting Agreement, dated February 27, 2025, by and between the Company and Sherry Aulin. |
|---|
| 2025-12-01 | 8-K | 10.1 | Amended and Restated 2025 Inducement Equity Plan and related form agreements. |
|---|
| 2025-10-17 | 8-K/A | 10.1 | Employment Agreement, dated October 4, 2025, by and between the Company and Thomas Kelly. |
|---|
| 2025-10-16 | 8-K | 10.1 | Employment Agreement, dated October 4, 2025, by and between the Company and Thomas Kelly. |
|---|
| 2025-08-11 | 10-Q | 10.2 | Employment Agreement, dated June 2, 2025, by and between the Company and Darren Cline. |
|---|
| 2025-08-11 | 10-Q | 10.1 | Form of Restricted Share Unit Award Agreement. |
|---|
| 2025-05-12 | 10-Q | 10.6 | Form of Performance Share Unit Award Agreement. |
|---|
| 2025-05-12 | 10-Q | 10.5 | Form of Restricted Share Unit Award Agreement. |
|---|
| 2025-02-27 | 10-K | 10.33 | Post-Employment Consulting Agreement, dated February 27, 2025, by and between the Company and Sherry Aulin. |
|---|
| 2025-02-27 | 10-K | 10.32 | 2025 Inducement Equity Incentive Plan and related form agreements. |
|---|
| 2025-02-27 | 10-K | 10.31 | Consulting Agreement, dated January 17, 2025, by and between the Company and Christopher Von Seggern. |
|---|
| 2025-02-27 | 10-K | 10.30 | Letter Agreement, dated January 15, 2025, by and between the Company and Christopher Von Seggern. |
|---|
| 2024-06-05 | 8-K | 10.1 | Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder. |
|---|
| 2024-05-09 | 10-Q | 10.1 | Form of Performance Share Award Agreement. |
|---|
| 2024-02-29 | 10-K | 10.28 | Employment Agreement, dated December 15, 2023, by and between the Company and James Empfield. |
|---|
| 2024-02-29 | 10-K | 10.27 | Consent to Alterations Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective August 16, 2023. |
|---|
| 2023-08-09 | 10-Q | 10.1 | Consent to Alterations Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective March 27, 2023. |
|---|
| 2023-03-14 | 8-K | 10.1 | Xenon Pharmaceuticals Inc. Executive Incentive Compensation Plan. |
|---|
| 2022-11-08 | 10-Q | 10.1 | Employment Agreement, dated November 7, 2022, by and between the Company and Andrea DiFabio. |
|---|
| 2022-08-09 | 10-Q | 10.1 | Consent to Alterations and Lease Modification Agreement between Redstone Enterprises Ltd. and Xenon Pharmaceuticals Inc., effective May 19, 2022. |
|---|
| 2022-06-02 | 8-K | 10.1 | Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder. |
|---|
| 2022-03-01 | 10-K | 10.30 | Amendment #2, dated February 25, 2022, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. |
|---|
| 2022-01-12 | 8-K | 10.1 | Share Purchase Agreement, dated as of January 11, 2022, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. |
|---|
| 2021-12-01 | 8-K | 10.1 | Lease Agreement, dated as of November 24, 2021, by and between the Company and Redstone Enterprises Ltd. |
|---|
| 2021-11-10 | 10-Q | 10.3 | Employment Agreement, dated August 18, 2021, by and between the Company and Christopher Kenney. |
|---|
| 2021-09-08 | 8-K | 10.1 | Share Purchase Agreement, dated as of September 8, 2021, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. |
|---|
| 2021-08-11 | 10-Q | 10.1 | Termination Agreement, dated August 6, 2021, by and among Xenon Pharmaceuticals Inc., Genentech, Inc. and F. Hoffmann-La Roche Ltd. |
|---|
| 2021-03-01 | 10-K | 10.33 | Lease Modification Agreement, effective October 5, 2020, by and between the Company and Redstone Enterprises Ltd. |
|---|
| 2021-03-01 | 10-K | 10.4 | Form of Share Option Agreement, as amended, under the Amended and Restated 2014 Equity Incentive Plan. |
|---|
| 2021-01-14 | 8-K | 10.4 | Employment Agreement, dated January 13, 2021, by and between the Company and Sherry Aulin. |
|---|
| 2021-01-14 | 8-K | 10.3 | Employment Agreement, dated January 13, 2021, by and between the Company and Simon Pimstone. |
|---|
| 2021-01-14 | 8-K | 10.2 | Employment Agreement, dated January 13, 2021, by and between the Company and Ian Mortimer. |
|---|
| 2021-01-14 | 8-K | 10.1 | Amendment #1, dated January 13, 2021, to the License and Collaboration Agreement, dated December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. |
|---|
| 2020-11-05 | 10-Q | 10.3 | Employment Agreement, dated July 17, 2020, by and between the Company and Christopher Von Seggern |
|---|
| 2020-08-06 | 10-Q | 10.2 | Amendment to Asset Purchase Agreement, dated August 4, 2020, by and between the Company and 1st Order Pharmaceuticals, Inc. |
|---|
| 2020-06-03 | 8-K | 10.1 | Amended and Restated 2014 Equity Incentive Plan and form of share option agreement used thereunder. |
|---|
| 2020-03-09 | 10-K | 10.25 | Amended and Restated Employment Agreement, dated March 20, 2019, by and between the Company and James Empfield. |
|---|
| 2020-03-09 | 10-K | 10.24 | Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Robin Sherrington. |
|---|
| 2019-12-02 | 8-K | 10.2 | Share Purchase Agreement, dated as of December 2, 2019, by and Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. |
|---|
| 2019-12-02 | 8-K | 10.1 | License and Collaboration Agreement, dated as of December 2, 2019, by and between Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. |
|---|
| 2019-09-10 | 8-K | 10.1 | 2019 Inducement Equity Incentive Plan and related form of share option agreement. |
|---|
| 2019-03-25 | 8-K | 10.7 | Form of Amended and Restated Employment Agreement (U.S. Executive). |
|---|
| 2019-03-25 | 8-K | 10.6 | Form of Offer of Employment (U.S. Executive). |
|---|
| 2019-03-25 | 8-K | 10.5 | Form of Amended and Restated Employment Agreement (CDN Executive). |
|---|
| 2019-03-25 | 8-K | 10.4 | Form of Offer of Employment (CDN Executive). |
|---|
| 2019-03-25 | 8-K | 10.3 | Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Ernesto Aycardi. |
|---|
| 2019-03-25 | 8-K | 10.2 | Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Ian Mortimer. |
|---|
| 2019-03-25 | 8-K | 10.1 | Amended and Restated Employment Agreement, dated March 19, 2019, by and between the Company and Simon Pimstone. |
|---|
| 2018-11-06 | 10-Q | 10.5 | Amended and Restated Amendment #7, dated September 27, 2018, to the Collaborative Research and License Agreement, dated December 22, 2011, by and among the Company, Genentech, Inc. and F. Hoffmann-La Roche Ltd, as amended. |
|---|
| 2018-09-11 | 8-K | 10.1 | Milestone and Royalty Buy-Out Agreement, dated September 7, 2018, by and among Xenon Pharmaceuticals Inc., Valeant Pharmaceuticals Ireland Limited and Valeant Pharmaceuticals Luxembourg S.a.r.l. |
|---|
| 2018-08-07 | 10-Q | 10.3 | Letter Amendment #7, dated July 25, 2018, to the Collaborative Research and License Agreement, dated December 22, 2011, by and among the Company, Genentech, Inc. and F. Hoffmann-La Roche Ltd, as amended. |
|---|
| 2018-08-07 | 8-K | 10.1 | Amended and Restated Loan and Security Agreement, dated August 3, 2018, by and among Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals USA Inc. and Silicon Valley Bank. |
|---|
| 2018-06-13 | 8-K | 10.1 | First Loan Modification to Loan and Security Agreement, dated June 12, 2018, by and among Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals USA Inc. and Silicon Valley Bank. |
|---|
| 2018-03-28 | 8-K | 10.1 | Exchange Agreement, dated March 23, 2018, by and among the Company and the shareholders listed in Schedule B thereto. |
|---|
| 2018-03-07 | 8-K | 10.1 | Termination Agreement by and among Xenon Pharmaceuticals Inc., Teva Pharmaceuticals International GmbH and Teva Canada Limited dated March 7, 2018 |
|---|
| 2017-12-18 | 8-K | 10.1 | Loan and Security Agreement, dated December 18, 2017, by and among Xenon Pharmaceuticals Inc., Xenon Pharmaceuticals USA Inc. and Silicon Valley Bank. |
|---|
| 2017-08-03 | 10-Q | 10.2 | Asset Purchase Agreement, dated April 25, 2017, by and between the Company and 1st Order Pharmaceuticals, Inc. |
|---|
| 2017-08-03 | 10-Q | 10.1 | Letter Agreement, dated May 8, 2017, to Amendment #4, dated May 13, 2015, to the Collaborative Research and License Agreement, dated December 22, 2011, by and among the Company, Genentech, Inc. and F. Hoffman-La Roche Ltd, as amended. |
|---|
| 2017-03-08 | 10-K | 10.20 | Offer letter, effective January 1, 2017, by and between Xenon Pharmaceuticals USA Inc. and James Empfield. |
|---|
| 2017-03-08 | 10-K | 10.8A | Form of Share Option Agreement, as amended, under the 2014 Equity Incentive Plan. |
|---|
| 2016-05-10 | 10-Q | 10.1 | Amendment #6, dated March 9, 2016, to the Collaborative Research and License Agreement, dated December 22, 2011, by and among the Company, Genentech, Inc. and F. Hoffman-La Roche Ltd., as amended. |
|---|
| 2016-03-08 | 10-K | 10.20 | Amendment #5, dated November 19, 2015, to the Collaborative Research and License Agreement, dated December 22, 2011, by and among the Company, Genentech, Inc. and F. Hoffman-La Roche Ltd, as amended. |
|---|
| 2016-03-08 | 10-K | 10.19 | Lease Modification Agreement, effective December 1, 2015, by and between the Company and Redstone Enterprises Ltd. |
|---|
| 2015-11-10 | 10-Q | 10.1 | Lease Modification Agreement, effective July 1, 2015, by and between the Company and Redstone Enterprises Ltd. |
|---|
| 2015-08-13 | 10-Q | 10.1 | Amendment #4, dated May 13, 2015, to the Collaborative Research and License Agreement, dated December 22, 2011, between Xenon Pharmaceuticals Inc. and Genentech, Inc. together with F. Hoffman-La Roche Ltd, as amended. |
|---|